[1] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60

[2] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

[3] Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein

[4] Severity of respiratory syncytial virus infection is related to virus strain

[5] Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children

[6] Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus

[7] Purification and characterization of the respiratory syncytial virus fusion protein